EC approves Astellas’ Xtandi for high-risk prostate cancer treatment
The European Commission (EC) has granted approval for label extension to Astellas’ Xtandi to be used as monotherapy or in combination with androgen deprivation therapy for treating adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone …